These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37506693)

  • 21. Multi-Influenza HA Subtype Protection of Ferrets Vaccinated with an N1 COBRA-Based Neuraminidase.
    Skarlupka AL; Zhang X; Blas-Machado U; Sumner SF; Ross TM
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
    Changsom D; Lerdsamran H; Wiriyarat W; Chakritbudsabong W; Siridechadilok B; Prasertsopon J; Noisumdaeng P; Masamae W; Puthavathana P
    PLoS One; 2016; 11(4):e0153183. PubMed ID: 27054879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.
    Manicassamy B; Medina RA; Hai R; Tsibane T; Stertz S; Nistal-Villán E; Palese P; Basler CF; García-Sastre A
    PLoS Pathog; 2010 Jan; 6(1):e1000745. PubMed ID: 20126449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
    Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
    J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.
    Yasuhara A; Yamayoshi S; Kiso M; Sakai-Tagawa Y; Okuda M; Kawaoka Y
    Nat Commun; 2022 Nov; 13(1):6602. PubMed ID: 36329075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.
    Wan H; Yang H; Shore DA; Garten RJ; Couzens L; Gao J; Jiang L; Carney PJ; Villanueva J; Stevens J; Eichelberger MC
    Nat Commun; 2015 Feb; 6():6114. PubMed ID: 25668439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets.
    Chen Z; Kim L; Subbarao K; Jin H
    Vaccine; 2012 Mar; 30(15):2516-22. PubMed ID: 22330124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imprinted Anti-Hemagglutinin and Anti-Neuraminidase Antibody Responses after Childhood Infections of A(H1N1) and A(H1N1)pdm09 Influenza Viruses.
    Daulagala P; Mann BR; Leung K; Lau EHY; Yung L; Lei R; Nizami SIN; Wu JT; Chiu SS; Daniels RS; Wu NC; Wentworth D; Peiris M; Yen HL
    mBio; 2023 Jun; 14(3):e0008423. PubMed ID: 37070986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
    Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
    PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.
    Kang HJ; Chu KB; Yoon KW; Eom GD; Mao J; Kim MJ; Lee SH; Moon EK; Quan FS
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.
    Cabral TM; Baig A; Berhane Y; Schmidt L; Hole K; Leith M; Kobasa D; Corbett CR
    J Virol Methods; 2014 Jan; 195():54-62. PubMed ID: 24060631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.
    Piepenbrink M; Oladunni F; Nogales A; Khalil AM; Fitzgerald T; Basu M; Fucile C; Topham DJ; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    Microbiol Spectr; 2023 Aug; 11(4):e0472822. PubMed ID: 37318331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.
    Cardoso FM; Ibañez LI; Van den Hoecke S; De Baets S; Smet A; Roose K; Schepens B; Descamps FJ; Fiers W; Muyldermans S; Depicker A; Saelens X
    J Virol; 2014 Aug; 88(15):8278-96. PubMed ID: 24829341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
    Benjamin E; Wang W; McAuliffe JM; Palmer-Hill FJ; Kallewaard NL; Chen Z; Suzich JA; Blair WS; Jin H; Zhu Q
    J Virol; 2014 Jun; 88(12):6743-50. PubMed ID: 24696468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009).
    Cabral TM; Berhane Y; Schmidt L; Tracz DM; Hole K; Leith M; Corbett CR
    J Virol Methods; 2012 Jul; 183(1):25-33. PubMed ID: 22575685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
    Broecker F; Zheng A; Suntronwong N; Sun W; Bailey MJ; Krammer F; Palese P
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31375573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.
    Job ER; Ysenbaert T; Smet A; Van Hecke A; Meuris L; Kleanthous H; Saelens X; Vogel TU
    mBio; 2019 Oct; 10(5):. PubMed ID: 31641082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.